




DRUG DISCOVERY

The Convergence of Biomarkers and Diagnostics

Therapy area analyses, key products and future trends

By Biophoenix

 [Table of Contents](#)

Biophoenix

Biophoenix is a biomedical consultancy that was founded by Dr Sreten Bogdanovic and Dr Beata Langlands. Established with support from the UK Department of Trade and Industry (DTI) in 1994, Biophoenix provides detailed, accurate, market and technical information to support decision-making by biotechnology-based enterprises in the healthcare industry. In doing so, Biophoenix relies on its comprehensive in-house bioindustry database and a wide network of contacts. Biophoenix also audits biotechnology-based enterprises with regard to the risk of intellectual property litigation on behalf of several Lloyds of London insurers. Further information is available on the internet at www.biophoenix.com.

Dr Bogdanovic is Managing Partner in Biophoenix. He holds a PhD in endocrinology from Imperial College, UK, and has worked as product manager for immunodiagnostics with the UK subsidiary of Boehringer Mannheim (now owned by Roche), and as an independent biomedical market analyst with Cistron, UK. Dr Langlands holds a PhD in biochemistry from the University of Glasgow, UK, and has worked as an immunologist, a project leader with a new biotechnology company based at Warwick University in the UK, and as a university lecturer. Biophoenix has researched and written over 50 in-depth management/market reports.

Copyright © 2008 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

The Convergence of Biomarkers and Diagnostics

Executive Summary	2	
Overview of biomarker-based diagnostics	2	
Biomarker discovery and validation	3	
Opportunities in cancer	4	
Opportunities in cardiovascular disease	6	
Opportunities in other diseases	7	
Market considerations and forecasts	8	
Trends and opportunities	10	
Chapter 1	Overview of biomarker-based diagnostics	12
Summary		12
Introduction		13
Information provided by biomarkers		14
DNA biomarkers		15
RNA biomarkers		15
Protein biomarkers		16
Metabolite biomarkers		16
Technologies for <i>in vitro</i> biomarker detection		17
Nucleic acid testing		18
Probe-based NAT		19
DNA microarrays		21
DNA methylation analysis		22
Gene expression analysis		23
Protein analysis		24
Immunoassays		24
Mass spectrometry		26
Multimarker diagnostic panels		27
Regulation of <i>in vitro</i> diagnostic tests		29
Europe		29
US		30

	Guidance on pharmacogenomic data submission	32
	Drug-diagnostic co-development concept paper	33
	Draft guidance on multivariate analysis	33
	In vivo biomarker diagnostics	37
Chapter 2	Biomarker discovery and validation	42
	Summary	42
	Introduction	43
	Omics approaches	43
	Genomics	44
	Transcriptomics	46
	Proteomics	46
	Metabolomics	50
	Other omics and systems biology	50
	Streamlining biomarker validation	51
	Case studies	54
	BG Medicine	54
	Caprion Proteomics	56
	Clinical Data	57
	Compugen	58
	Digilab Peptidomics	59
	Metabolon	60
	Monarch LifeSciences	61
	Pronota	62
	Source MDx	63
	Vermillion	64
Chapter 3	Opportunities in cancer	68
	Summary	68
	Background on cancer	69
	Biomarker-based diagnostics	71
	Targeted therapies and companion diagnostics	73
	Tests based on DNA biomarkers	74
	Tests based on RNA biomarkers	77
	Tests based on protein biomarkers	78
	Biomarkers in breast cancer	80
	Susceptibility	80
	Detection	81
	Prognosis and selection for therapy	83

Chemotherapy	85
Tamoxifen	87
HER2-targeting treatments	88
Biomarkers in prostate cancer	90
Susceptibility	90
Detection	91
Classification, prognosis, and treatment	93
Biomarkers in colorectal cancer	94
Susceptibility	95
Detection	96
Classification, prognosis, and treatment	97
Biomarkers in lung cancer	100
Susceptibility	100
Detection	101
Classification, prognosis, and treatment	102
Biomarkers in ovarian cancer	104
Detection	104
Classification and prognosis	106

Chapter 4 Opportunities in cardiovascular diseases 110

Summary	110
Background on cardiovascular disease	111
Biomarker-based diagnostics	112
Tests based on protein biomarkers	113
Tests based on other biomarkers	116
Biomarkers in coronary artery disease	118
Lipid/lipoprotein biomarkers	119
Biomarkers of inflammation, plaque instability	121
Genetic biomarkers	124
Biomarkers from omic studies	127
Biomarkers in acute coronary syndromes	129
Biomarkers of necrosis	129
Other biomarkers	131
Biomarkers for risk stratification	132
Multimarker strategies	133
Biomarkers in congestive heart failure	136
Biomarkers of hemodynamic strain	136
Pharmacogenomic biomarkers	137
Biomarkers in stroke	138
Prediction of drug efficacy	140

Chapter 5 Opportunities in other diseases 144

Summary	144
Biomarkers in infectious diseases	145
Viral infections	147
HIV	147
Hepatitis viruses	149
HPV	151
Influenza and SARS	152
Bacterial infections	153
Chlamydia and gonorrhea	153
Mycobacteria	154
MRSA	155
Sepsis screening	156
Biomarkers in CNS disorders	157
Alzheimer's disease	157
Other neurodegenerative disorders	161
Multiple sclerosis	163
Traumatic brain injury	164
Biomarkers of CNS drug efficacy	164
Biomarkers in diabetes and obesity	167
Type 1 diabetes	167
Obesity and type 2 diabetes	168

Chapter 6 Market considerations and forecasts 174

Summary	174
Introduction	175
Overview of the total pharmaceuticals market	175
Overview of the total <i>in vitro</i> diagnostics market	175
Outlook for the diagnostic biomarkers market	179
Cancer: immunoassays and microarrays	181
Cardiovascular disease: immunoassays	183
Infection biomarkers	184
Predisposition and pharmacogenomic tests	185

Chapter 7 Trends and opportunities 188

Summary	188
Prospects for omics-derived biomarkers	189
Genomic variants as biomarkers	190

Gene expression signatures as biomarkers	190
Proteomic patterns as biomarkers	191
Translating omic discoveries into immunoassays	192
Factors affecting acceptance of biomarkers	193
Prospects for companion diagnostics	194
Biomarkers patent survey	195

Chapter 8 Appendix 208

Research Methodology	208
Proteomic Cancer Biomarkers	208
Biomarkers of Cardiovascular Disease and Stroke	208
Index	254

List of Figures

Figure 4.1: Biomarkers of Acute Coronary Syndromes	134
---	-----

List of Tables

Table 1.1: In Vitro Diagnostic Multivariate Index Assays - FDA Draft Guidance (July, 07)	34
Table 4.2: Further Biomarkers of Cardiovascular Disease and Stroke	116
Table 6.3: Worldwide In Vitro Diagnostic Sales by Country 2007-2012 (\$m)	177
Table 6.4: Worldwide In Vitro Diagnostic Sales by Application 2007-12 (\$m)	178
Table 6.5: Biomarker Markets by Application 2007-2012 (\$m)	180
Table 6.6: Biomarker Markets by Geographical Region 2007-2012 (\$m)	181
Table 7.7: Analysis of filling and publication dates for biomarker patents, 2000-2007	197
Table 7.8: Biomarker assignees with six or more patents	198
Table 7.9: Biomarker patents: technologies and applications	199
Table 7.10: Biomarker assignees with six or more patents	201
Table 7.11: Patent activity analysis for top four biomarker assignees, Part 1	204
Table 7.12: Patent activity analysis for top four biomarker assignees, Part 2	205
Table 8.13: High Priority Proteomic Cancer Biomarkers	209
Table 8.14: Other Proteomic Cancer Biomarkers	217
Table 8.15: Biomarkers of Cardiovascular Disease and Stroke	246